In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merck, Pfizer team up on Phase III trials and future commercialization of Pfizer's SGLT2 inhibitor for Type II diabetes

Executive Summary

Merck & Co. Inc. and Pfizer Inc. have entered into a worldwide (excluding Japan) collaboration surrounding the development and commercialization of Pfizer’s oral sodium-dependent glucose cotransporter (SGLT2) inhibitor ertugliflozin (PF04971729), which will enter Phase III trials for Type II diabetes later this year.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies